leadf
logo-loader
viewTRACON Pharmaceuticals

TRACON says publication of clinical data in Cancer Cell journal provides molecular insight into TRC102

The article identified the cancer patient populations most likely to respond to treatment to TRACON’s drug TRC102

TRACON Pharmaceuticals -
The compny is committed to developing TRC102 in collaboration with the National Cancer Institute and believes the data generated to date provide a rationale to study TRC102 in combination with Temodar and radiotherapy in newly diagnosed patients with malignant glioma

TRACON Pharmaceuticals Inc (NASDAQ:TCON), which develops a clinical-stage pipeline of cancer therapies, announced the publication in the Cancer Cell journal of clinical data that provides molecular insight into its drug TRC102’s mechanism of action and the patient populations most likely to respond to treatment.

The article, entitled, “Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment,” highlighted the clinical features and tumor biology of an exceptional responder patient treated with TRC102 at the National Cancer Institute (NCI).

The San Diego, California-based company said the patient was diagnosed with metastatic and highly refractory colorectal cancer and received temozolomide (Temodar) and TRC102. Following treatment, the patient was considered an “exceptional responder” through the achievement of a near complete response lasting “45 months at the most recent follow-up.”

READ: TRACON wins FDA Orphan Drug status for TRC102 in malignant glioma

TRACON said detailed molecular analyses of the patient’s tumor showed “silencing of DNA repair pathways that may have resulted in sensitivity to the inhibition of DNA base excision repair pathway by TRC102.” The authors hypothesized that the Temodar and TRC102 combo was effective because all necessary DNA repair pathways were “compromised genetically or through the activity of TRC102.”

“O6-Methylguanine-DNA-methyltransferase (MGMT) expression was also assessed in biopsies from 11 colorectal patients who subsequently enrolled in an expansion cohort, one of which demonstrated a partial response,” said the company. The tumor linked to the partial response did nog express MGMT, whereas each of the 10 tumors that did not respond to therapy expressed this enzyme robustly.

TRC102 is being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the NCI through a Cooperative Research and Development Agreement (CRADA). TRC102 was evaluated in a Phase 2 trial in combination with Temodar chemotherapy in 19 patients with progressive or recurrent glioblastoma, who progressed following Temodar and external beam radiotherapy.

Extended survival was observed in two patients for more than two years, both of whom demonstrated activation of the DNA base excision repair pathway and showed hyperactivation of DNA damage response genes prior to treatment with TRC102, said the company.

“The Cancer Cell publication supports our belief that patients whose cancers are dependent on the DNA base excision repair pathway to repair DNA damage from chemotherapy may be particularly sensitive to the pharmacologic effects of TRC102,” said TRACON chief Medical Officer James Freddo.

“The NCI data are also consistent with the results from the Phase 2 trial of Temodar and TRC102 in refractory glioblastoma. We remain committed to developing TRC102 in collaboration with the NCI and believe that the data generated to date provide strong rationale for studying TRC102 in combination with Temodar and radiotherapy in newly diagnosed patients with malignant glioma.”

In October this year, TRC102 was granted orphan drug designation by the US Food and Drug Administration for the treatment of malignant glioma, including glioblastoma, an aggressive type of cancer that can occur in the brain or spinal cord.

With orphan designation, TRACON qualifies for various incentives with respect to TRC102 for the treatment of glioblastoma, including tax credits for qualified clinical trials.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Quick facts: TRACON Pharmaceuticals

Price: 9.17 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $133.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

TRACON's partners submit new drug application for approval of envafolimab to...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug application for the approval of envafolimab in the indication of MSI-H/dMMR cancer to the National Medical Products Administration in...

on 11/19/2020

3 min read